Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With an Open-Label Extension Investigating Efficacy, Safety, and Tolerability of Encaleret in Participants With Chronic Hypoparathyroidism

NCT07805356 is registered in ClinicalTrials.gov with Calcilytix Therapeutics, Inc., a BridgeBio company as lead sponsor.

NCT NCT07805356
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07805356 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With an Open-Label Extension Investigating Efficacy, Safety, and Tolerability of Encaleret in Participants With Chronic Hypoparathyroidism
Lead sponsor
Calcilytix Therapeutics, Inc., a BridgeBio company
Phase
Phase 3
Overall status
Recruiting
Start date
August 31, 2026
Completion date
January 31, 2033
Enrollment
160 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hypoparathyroidism, hypoparathyroidism